Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jonathan W. Riess, Mark D. Krailo, Sukhmani Kaur Padda, Susan G. Groshen, Heather A. Wakelee, Karen L. Reckamp, Marianna Koczywas, Zofia Piotrowska, Conor Ernst Steuer, Chul Kim, Cloud P. Paweletz, Lynette M. Sholl, Grace Heavey, Jill Kolesar, Jeffrey Moscow, Pasi A. Janne, Primo "Lucky" N. Lara, Edward M. Newman, David R. Gandara
Institutions: UC Davis Comprehensive Cancer Center, Children's Oncology Group, Cedars-Sinai Medical Center, University of Southern California, Stanford Cancer Institute, City Of Hope National Medical Center, Massachusetts General Hospital, Winship Cancer Institute, Dana-Farber Cancer Institute, Brigham and Women's Hospital, University of Kentucky, National Cancer Institute, University of California System, University of California Davis Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W4281616728